Literature DB >> 16554260

Therapeutics in duchenne muscular dystrophy.

Jonathan B Strober1.   

Abstract

Duchenne muscular dystrophy (DMD) is a fatal disorder affecting approximately 1 in 3,500 live born males, characterized by progressive muscle weakness. Several different strategies are being investigated in developing a cure for this disorder. Until a cure is found, therapeutic and supportive care is essential in preventing complications and improving the afflicted child's quality of life. Currently, corticosteroids are the only class of drug that has been extensively studied in this condition, with controversy existing over the use of these drugs, especially in light of the multiple side effects that may occur. The use of nutritional supplements has expanded in recent years as researchers improve our abilities to use gene and stem cell therapies, which will hopefully lead to a cure soon. This article discusses the importance of therapeutic interventions in children with DMD, the current debate over the use of corticosteroids to treat this disease, the growing use of natural supplements as a new means of treating these boys and provides an update on the current state of gene and stem cell therapies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16554260      PMCID: PMC3593432          DOI: 10.1016/j.nurx.2006.01.005

Source DB:  PubMed          Journal:  NeuroRx        ISSN: 1545-5343


  96 in total

1.  Dystrophin expression in the mdx mouse restored by stem cell transplantation.

Authors:  E Gussoni; Y Soneoka; C D Strickland; E A Buzney; M K Khan; A F Flint; L M Kunkel; R C Mulligan
Journal:  Nature       Date:  1999-09-23       Impact factor: 49.962

2.  Immune rejection of human dystrophin following intramuscular injections of naked DNA in mdx mice.

Authors:  S Braun; C Thioudellet; P Rodriguez; D Ali-Hadji; F Perraud; N Accart; J M Balloul; C Halluard; B Acres; B Cavallini; A Pavirani
Journal:  Gene Ther       Date:  2000-09       Impact factor: 5.250

Review 3.  Current concepts of respiratory complications of neuromuscular disease in children.

Authors:  C M Schramm
Journal:  Curr Opin Pediatr       Date:  2000-06       Impact factor: 2.856

4.  Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model.

Authors:  B Wang; J Li; X Xiao
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

5.  Phase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophy.

Authors:  Norma B Romero; Serge Braun; Olivier Benveniste; France Leturcq; Jean-Yves Hogrel; Glenn E Morris; Annie Barois; Bruno Eymard; Christine Payan; Véronique Ortega; Anne-Laure Boch; Lise Lejean; Christine Thioudellet; Brigitte Mourot; Christophe Escot; Aurore Choquel; Dominique Recan; Jean-Claude Kaplan; George Dickson; David Klatzmann; Valérie Molinier-Frenckel; Jean-Gérard Guillet; Patrick Squiban; Serge Herson; Michel Fardeau
Journal:  Hum Gene Ther       Date:  2004-11       Impact factor: 5.695

6.  A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy.

Authors:  G M Fenichel; R C Griggs; J Kissel; T I Kramer; J R Mendell; R T Moxley; A Pestronk; K Sheng; J Florence; W M King; S Pandya; V D Robison; H Wang
Journal:  Neurology       Date:  2001-04-24       Impact factor: 9.910

7.  Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice.

Authors:  E R Barton-Davis; L Cordier; D I Shoturma; S E Leland; H L Sweeney
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

8.  Deflazacort treatment of Duchenne muscular dystrophy.

Authors:  W D Biggar; M Gingras; D L Fehlings; V A Harris; C A Steele
Journal:  J Pediatr       Date:  2001-01       Impact factor: 4.406

9.  Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.

Authors:  R T Moxley; S Ashwal; S Pandya; A Connolly; J Florence; K Mathews; L Baumbach; C McDonald; M Sussman; C Wade
Journal:  Neurology       Date:  2005-01-11       Impact factor: 9.910

10.  A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy.

Authors:  M D Bonifati; G Ruzza; P Bonometto; A Berardinelli; K Gorni; S Orcesi; G Lanzi; C Angelini
Journal:  Muscle Nerve       Date:  2000-09       Impact factor: 3.217

View more
  10 in total

Review 1.  Gene therapy for muscular dystrophy: moving the field forward.

Authors:  Samiah Al-Zaidy; Louise Rodino-Klapac; Jerry R Mendell
Journal:  Pediatr Neurol       Date:  2014-08-07       Impact factor: 3.372

2.  Pediatric neurotherapy.

Authors:  Leon S Dure; Faye Silverstein
Journal:  NeuroRx       Date:  2012-09-05

3.  Longitudinal Evaluation of Muscle Composition Using Magnetic Resonance in 4 Boys With Duchenne Muscular Dystrophy: Case Series.

Authors:  Claudia R Senesac; Donovan J Lott; Sean C Forbes; Sunita Mathur; Ishu Arpan; Emily S Senesac; Glenn A Walter; Krista Vandenborne
Journal:  Phys Ther       Date:  2015-01-15

4.  Quantitative assessment of the T2 relaxation time of the gluteus muscles in children with Duchenne muscular dystrophy: a comparative study before and after steroid treatment.

Authors:  Hee Kyung Kim; Tal Laor; Paul S Horn; Brenda Wong
Journal:  Korean J Radiol       Date:  2010-04-29       Impact factor: 3.500

5.  Use of pifithrin to inhibit p53-mediated signalling of TNF in dystrophic muscles of mdx mice.

Authors:  Felicity J Waters; Thea Shavlakadze; Matthew J McIldowie; Matthew J Piggott; Miranda D Grounds
Journal:  Mol Cell Biochem       Date:  2009-10-27       Impact factor: 3.396

6.  Observations of body mass index in Duchenne muscular dystrophy: a longitudinal study.

Authors:  Z E Davidson; M M Ryan; A J Kornberg; K Sinclair; A Cairns; K Z Walker; H Truby
Journal:  Eur J Clin Nutr       Date:  2014-05-14       Impact factor: 4.016

7.  Exon skipping and gene transfer restore dystrophin expression in human induced pluripotent stem cells-cardiomyocytes harboring DMD mutations.

Authors:  Emily Dick; Spandan Kalra; David Anderson; Vinoj George; Morten Ritso; Steven H Laval; Rita Barresi; Annemieke Aartsma-Rus; Hanns Lochmüller; Chris Denning
Journal:  Stem Cells Dev       Date:  2013-07-05       Impact factor: 3.272

8.  Muscle reorganisation through local injection of stem cells in the diaphragm of mdx mice.

Authors:  Thais Borges Lessa; Rafael Cardoso Carvalho; André Luis Rezende Franciolli; Lilian Jesus de Oliveira; Rodrigo Silva da Nunes Barreto; David Feder; Fabiana Fernandes Bressan; Maria Angélica Miglino; Carlos Eduardo Ambrósio
Journal:  Acta Vet Scand       Date:  2012-12-12       Impact factor: 1.695

9.  Motor physical therapy affects muscle collagen type I and decreases gait speed in dystrophin-deficient dogs.

Authors:  Thaís P Gaiad; Karla P C Araujo; Júlio C Serrão; Maria A Miglino; Carlos Eduardo Ambrósio
Journal:  PLoS One       Date:  2014-04-08       Impact factor: 3.240

10.  Genetic correction of splice site mutation in purified and enriched myoblasts isolated from mdx5cv mice.

Authors:  Katie Maguire; Takayuki Suzuki; Darlise DiMatteo; Hetal Parekh-Olmedo; Eric Kmiec
Journal:  BMC Mol Biol       Date:  2009-02-23       Impact factor: 2.946

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.